Article Text

Download PDFPDF

P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial
  1. Paula K Schweitzer1,
  2. Geert Mayer2,3,
  3. Russell Rosenberg4,5,
  4. Gary K Zammit6,7,
  5. Mark Gotfried8,
  6. Dan Chen9,
  7. Lawrence P Carter9,10,
  8. Hao Wang11,
  9. Jed Black8,12,
  10. Atul Malhotra13 and
  11. Kingman P Strohl14
  1. 1Sleep Medicine and Research Center, St. Luke’s Hospital, Chesterfield, USA
  2. 2Hephata Klinik, Schwalmstadt, Germany
  3. 3Philipps University Marburg, Marburg, Germany
  4. 4NeuroTrialsResearch, Inc., Atlanta, USA
  5. 5Atlanta School of Sleep Medicine, Atlanta, USA
  6. 6Clinilabs Drug Development Corporation, New York, USA
  7. 7Icahn School of Medicine at Mount Sinai, New York, USA
  8. 8Pulmonary Associates, Phoenix, USA
  9. 9Jazz Pharmaceuticals, Palo Alto, USA
  10. 10University of Arkansas for Medical Sciences, Little Rock, USA
  11. 11Kite Pharma, Inc., Santa Monica, USA, (previously from Jazz Pharmaceuticals, Palo Alto, CA, USA)
  12. 12Stanford Center for Sleep Sciences and Medicine, Palo Alto, USA
  13. 13Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, USA
  14. 14Case Western Reserve University, Cleveland, USA


Introduction Obstructive sleep apnoea (OSA) is often associated with persistent excessive daytime sleepiness (EDS) despite sleep apnoea therapy. There are currently no approved treatments in the European Union for the treatment of EDS in this population. Solriamfetol (formerly JZP-110), a dopamine and norepinephrine reuptake inhibitor, has been approved in the United States to improve wakefulness in adults with EDS associated with narcolepsy (75–150 mg) or OSA (37.5–150 mg). A Marketing Authorisation Application for these indications is under review with the European Medicines Agency. This study evaluated the efficacy and safety of solriamfetol for treatment of EDS in participants with OSA with current or prior sleep apnoea treatment.1

Methods In this double-blind, placebo-controlled, parallel-group phase 3 trial, participants with OSA and associated EDS were randomly assigned to solriamfetol 37.5 mg, 75 mg, 150 mg, or 300 mg or placebo for 12 weeks.

Results Of 476 randomised participants, 459 were included in the prespecified efficacy analyses. Co-primary endpoints (Maintenance of Wakefulness Test sleep latency, Epworth Sleepiness Scale score) were met at all solriamfetol doses (P<0.05), with dose-dependent effects observed at week 1 and maintained over the study duration. All doses except 37.5 mg resulted in significantly higher percentages of participants reporting improvement on Patient Global Impression of Change (key secondary endpoint; P<0.05). Adverse events (AEs) were reported in 47.9% of placebo- and 67.9% of solriamfetol-treated participants; 5 participants experienced serious AEs (2 [1.7%] placebo, 3 [0.8%] solriamfetol); none were deemed related to study drug. The most common AEs with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%).

Discussion Solriamfetol significantly improved wakefulness and reduced sleepiness in participants with OSA and EDS. Most AEs were mild or moderate.

Support Jazz Pharmaceuticals.


  1. Schweitzer PK, et al. Am J Respir Crit Care Med 2019:199(11)1421–1431.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.